Activating a protein in red blood cells may improve anemia and alleviate acute episodes of severe pain for people living with sickle cell disease Swee Lay Thein, M.B., D.Sc., a senior investigator and chief of NHLBI’s Sickle Cell Branch, shares insight into a decade-long research journey that may lead to new ways to help people living with sickle...
Showing 10 out of 1603 results
Researchers are reporting for the first time that cardiovascular disease affects the blood vessels in the bone marrow and leads to increased production of white blood cells that drive inflammation.
Researchers are reporting new details on how a diet rich in red meat can harm the heart.
Black patients with chest pain tend to have more risk factors for cardiovascular disease (CVD) compared to white patients, but they both have a similarly low incidence of major adverse cardiac events over a two-year period.
Researchers identified disparities related to controlling high blood pressure among U.S. adults and shared suggested strategies to strengthen health equity.
Researchers are reporting that people with chest pain and limited English proficiency are less likely to be diagnosed with heart disease in the United States compared to fluent English speakers.
An experimental gene therapy approach for treating sickle cell disease shows promise for eliminating painful crises that are associated with the condition, according to interim findings from a clinical trial.
Researchers have linked a rare genetic mutation found mostly in Black Americans and other people of African descent to an earlier onset of heart failure and a higher risk of hospitalization.
A small clinical trial supported by the NIH has found that eating during the nighttime—like many shift workers do—can increase glucose levels.
Researchers are reporting the identification of more than a dozen metabolic biomarkers that may influence the development of coronary heart disease (CHD) in African Americans.
Sixteen out of 18 men who received gene therapy for hemophilia A, an inherited bleeding disorder, experienced an annual reduction in bleeding events. Researchers found no major safety concerns and continue to follow participants to evaluate the safety and effectiveness of this type of gene therapy.